Short-Term Pipeline

Alcon is developing new products to treat diseases and conditions in all key eye care categories: surgical, pharmaceutical and consumer vision care products. We also have targeted development activities in the otic and nasal areas.

To balance resource use with the strongest likelihood of success, Alcon continuously evaluates its pipeline products to determine the most promising projects to advance through the many phases of clinical testing. The following table includes additional detail about each of these products in development, including the expected regulatory submission date in the U.S. Submissions to regulatory bodies outside of the U.S. may have a different timeline.

To see complete details about Alcon activity, see our latest SEC filing, 20-F.

Category & Name Condition Expected Submission Date* Status at December 31, 2008 (1)
Pharmaceutical
DuoTrav Glaucoma Jpn Filed Filed
Aganocide Anti-infective U.S. 2011 or later Phase I/II
    EU 2011 or later  
    Jpn 2011 or later  
Vigamox® Anti-infective EU Filed Filed
Moxifloxacin, new formulation Anti-infective U.S. Filed (2) Filed
NEVANAC® Anti-inflammatory Jpn Filed Filed
AL-43,546 Dry eye U.S. 2011 or later Phase I/II
    EU 2011 or later  
    Jpn 2011 or later  
Hyaluronic acid (3) Dry eye U.S. 2009 Pre-submission
Triesence® injectable suspension Retinal surgery EU 2009 Pre-submission
    Jpn 2009 Pre-submission
Otic/Nasal
Moxifloxacin/
dexamethasone
Anti-infective & anti-inflammatory U.S. 2011 or later (2) Phase III
Patanase® pediatric Allergy U.S. 2009 Phase III
Surgical
AcrySof ® Toric diopter range expansion Cataract U.S. 2011 or later Advanced development
    EU 2009 Advanced development
AcrySof ® ReSTOR® diopter range expansion Cataract U.S 2009 Advanced development
    EU 2009 Advanced development
AcrySof ® ReSTOR® Aspheric, +3.0 add lens Cataract Jpn 2009 Advanced development
AcrySof ® ReSTOR® Toric lens Cataract U.S. 2011 or later Advanced development
    EU 2011 or later  
    Jpn 2011 or later  
AcrySof ® angle-supported phakic lens Refractive U.S. 2009 Advanced development
    Jpn 2011 or later  
DisCoVisc® viscoelastic Cataract Jpn Filed Filed
Consumer Vision Care
Systane® Ultra unit dose Dry eye U.S. 2009 Advanced development
Systane® ORB Dry eye U.S. 2009 Advanced development
OPTI-FREE® multi-purpose solution Lens solution Jpn Filed Filed
OPTI-FREE® silicone hydrogel Lens solution U.S. 2010 Early development
    EU 2010 Early development
ICAPS® next generation Ocular vitamin U.S. 2009 Advanced development
    EU 2009 Advanced development
ICAPS® AREDS2 Ocular vitamin U.S. 2011 or later Early development
    EU 2011 or later Early development

 

(1) For a description of the FDA approval process, see "Government Regulation" in our 20F filed with the SEC.

(2) The FDA issued a notice in the fall of 2007 advising companies that they were increasing the requirements
for anti-infective clinical studies and that clinical programs previously agreed upon may not be sufficient to
support approval. As a result, additional Phase III clinical studies may be required for approval.

(3) This project is being managed and conducted by River Plate Biotechnology, Inc., which filed its NDA in
January 2009.

 

back to top